Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal
Shares in Liquidia rose after the U.S. Supreme Court rejected an appeal by United Therapeutics in the fellow biotech company's patent dispute. Shares were recently up 12% at $11.20. The court rejected United's appeal over a decision to invalidate its patent claims concerning Liquidia's drug Yutrepia,